Phylonix Phase II SBIR To Develop Zebrafish Models For Eye Diseases
Phylonix Pharmaceuticals, Inc. has announced that it has been awarded a $1,092,031 Phase II Small Business Innovation Grant (SBIR) from the National Eye Institute of the National Institutes of Health (NIH) to develop zebrafish eye disease models for drug screening. The grant for “New Models for Eye Diseases” will support the Phylonix program over a period of three years.
